DECISION OF THE EEA JOINT COMMITTEE No 16/2024

of 2 February 2024

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ("the EEA Agreement"), and in particular Article 98 thereof,

Whereas:


- (1) Commission Implementing Regulation (EU) 2023/515 of 8 March 2023 renewing the approval of the active substance abamectin in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 is to be incorporated into the EEA Agreement.
- (2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XV of Annex II to the EEA Agreement shall be amended as follows:

- 1. The following indent is added in point 13a (Commission Implementing Regulation (EU) No 540/2011):
 - '- **32023 R 0515**: Commission Implementing Regulation (EU) 2023/515 of 8 March 2023 (OJ L 71, 9.3.2023, p. 22).'
- 2. The following point is inserted after point 13zzzzzzzzzzzj (Commission Implementing Regulation (EU) 2023/2016):



Article 2

The text of Implementing Regulation (EU) 2023/515 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

_

OJ L 71, 9.3.2023, p. 22.

Article 3

This Decision shall enter into force on 3 February 2024, provided that all the notifications under Article 103(1) of the EEA Agreement have been made*.

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 2 February 2024.

For the EEA Joint Committee The President

Nicolas von Lingen

The Secretaries
To the EEA Joint Committee

Siri Veseth Meling

Matúš Minárik

EN 2 EN

^{*} No constitutional requirements indicated.